Zynex (OTCMKTS:ZYXI) Stock Price Up 5.2%

Zynex Inc. (OTCMKTS:ZYXI)’s share price traded up 5.2% on Wednesday . The stock traded as high as $8.70 and last traded at $8.65. 212,383 shares changed hands during mid-day trading, an increase of 137% from the average session volume of 89,663 shares. The stock had previously closed at $8.22.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. B. Riley reaffirmed a “buy” rating on shares of Zynex in a research note on Friday, February 22nd.

The company has a market cap of $251.19 million, a price-to-earnings ratio of 39.32 and a beta of 1.05.

Zynex (OTCMKTS:ZYXI) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $8.45 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. As a group, research analysts expect that Zynex Inc. will post 0.28 EPS for the current fiscal year.

In related news, CEO Thomas Sandgaard sold 48,008 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $4.40, for a total transaction of $211,235.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Moorhead sold 13,750 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $8.25, for a total value of $113,437.50. The disclosure for this sale can be found here. Insiders have sold a total of 489,150 shares of company stock worth $3,098,466 over the last three months.

Institutional investors have recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP acquired a new position in shares of Zynex in the 1st quarter valued at approximately $45,000. Sigma Planning Corp acquired a new position in shares of Zynex in the 1st quarter valued at approximately $63,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $118,000. WealthTrust Axiom LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $132,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Zynex in the 1st quarter valued at approximately $215,000. 0.05% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zynex (OTCMKTS:ZYXI) Stock Price Up 5.2%” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.themarketsdaily.com/2019/06/13/zynex-otcmktszyxi-stock-price-up-5-2.html.

About Zynex (OTCMKTS:ZYXI)

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Further Reading: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.